The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-ONcology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.
 
Praveen Aanur
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb (Inst)
 
Martin Gutierrez
Stock and Other Ownership Interests - COTA
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Foundation One Inc; Merck
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Esanex (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Rexahn Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Ronan Joseph Kelly
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Lilly; Novartis; OncoMed
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
 
Jaffer A. Ajani
Honoraria - Bayer; Five Prime Therapeutics; Genentech; Lilly/ImClone; Novartis; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Crystal Shereen Denlinger
Consulting or Advisory Role - Carevive Systems; EMD Serono; Lilly; Merrimack
Research Funding - Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst)
 
Thomas J. George
Consulting or Advisory Role - Bayer; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst)
 
Megan Wind-Rotolo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Xiaowei Guan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Manish Gupta
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Timothy P. Reilly
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Paula M. Fracasso
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb